On October 30, 2024 Experimental Drug Development Centre reported in September 2024, the company showcased our phase 1 dose escalation study for EBC-129 (NCT05701527) at European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress (Press release, Experimental Drug Development Centre, OCT 30, 2024, View Source [SID1234654015]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Further to the ESMO (Free ESMO Whitepaper) poster presentation, we are happy to announce that we have completed enrolment of the pancreatic ductal adenocarcinoma (PDAC) cohort in the ongoing dose expansion part of EBC-129’s Phase 1 study!

Enrollment in cohorts with gastroesophageal adenocarcinomas and the cohort with other IHC positive solid tumours is ongoing.

Find more details about trial at:

Study Details | A Study of EBC-129 in Advanced Solid Tumours | ClinicalTrials.gov